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SUMMARY
OBJECTIVE: To calculate the per-session and annual direct program costs to implement directly 
observed therapy (DOT) for tuberculosis treatment and to conduct a cost attribution analysis under 
varying proportions of DOT utilization for four DOT types.
DESIGN: Program data covering the study period from September 2014 to August 2015 in New 
York City (NYC) were used to conduct a retrospective bottom-up micro-costing economic 
evaluation. For each DOT type, potential per-session and annual program savings were estimated 
as the cost averted by adopting a uniform distribution of DOT alternatives. Sensitivity analyses 
explored aggregate cost impacts of unequal distributions.
RESULTS: There was a total of 38 035 unique DOT visits, of which 12 002 (32%) were clinic-
based (CDOT); 15 483 (41%) were field-based (FDOT); 7185 (19%) were live-video (LVDOT); 
and 3365 (9%) were recorded-video (RVDOT). The per-session direct costs (in 2016 $US) for 
DOT services delivered during the study period were $8.46 for CDOT; $19.83 for FDOT; $6.54 
for LVDOT; and $5.35 for RVDOT. Sensitivity analyses supported the main findings.
CONCLUSIONS: Significant cost savings were estimated with increased utilization of VDOT. 
Assuming equivalent treatment adherence, duration, completion, and adverse events across DOT 
types, RVDOT was the modality that most minimized cost.
RESUME
Calculer les coûts directs du programme par session et par an en termes de mise en œuvre de la 
thérapie sous observation directe (DOT) pour le traitement de la tuberculose et de réaliser une 
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analyse d’attribution des coûts en fonction des variations du taux d’utilisation des DOT dans 
quatre types de DOT.
Les données de programme couvrant la période d’étude, de septembre 2014 à août 2015, dans la 
ville de New York (NYC) ont été utilisées pour réaliser une évaluation économique rétrospective 
participative des micro coûts. Pour chaque stratégie de DOT, les économies potentielles pour le 
programme par session et par an ont été; estimées comme le coût évité en adoptant une 
distribution uniforme des alternatives au DOT. Les analyses de sensibilité ont exploré les impacts 
de coût aggrégé des distributions inégales.
Le nombre total de DOT uniques a été de 38 035, avec la distribution suivante—DOT en structures 
de santé (CDOT), 12 002 (32%); DOT sur le terrain (FDOT), 15 483 (41%); DOT sous vidéo en 
temps réel (LVDOT), 7185 (19%); et sous vidéo enregistrée (RVDOT), 3365 (9%). Les coûts 
directs par session (en $US 2016) pour les services DOT fournis pendant la période d’étude ont été 
de 8,46$ pour les CDOT; de 19,83$ pour les FDOT; de 6,54$ pour les LVDOT; et de 5,35$ pour 
les RVDOT. Les analyses de sensibilité ont confirmé les principaux résultats.
Des économies significatives ont été estimées grâce à l’utilisation accrue des VDOT. Les RVDOT 
ont été la modalité de réduction des coûts en admettant que l’observance au traitement, sa durée, 
son achèvement et les effets secondaires sont équivalents dans toutes les stratégies de DOT.
RESUMEN
Calcular los costos programáticos por sesión y los costos anuales directos de la ejecución del 
tratamiento antituberculoso con observación directa (DOT) y realizar un análisis de atribución de 
costos en diferentes situaciones hipotéticas de la proporción de utilizatión de cuatro tipos de DOT.
Se utilizaron los datos del programa de septiembre del 2014 a agosto del 2015 de la ciudad de 
Nueva York, con el fin de realizar una evaluatión económica de tipo ascendente del análisis 
detallado de los costos. Para cada tipo de DOT se calcularon los posibles ahorros para el programa 
por sesión y anuales como el costo evitado al adoptar una distributión uniforme de las otras 
opciones de DOT. Mediante un análisis de sensibilidad se evaluaron los efectos del costo agregado 
de las distribuciones desiguales.
El número total de citas únicas por DOT fue 38 035, con la siguiente distributión: en consultorio 
(CDOT), 12 002 (32%); en el terreno (FDOT), 15 483 (41%); con video directo (LVDOT), 7185 
(19%); y con video grabado (RVDOT), 3365 (9%). Los costos directos por sesión (en $US del 
2016) por los servicios de DOT prestados durante el período del estudio fueron como sigue: 8,46 
$US por CDOT; 19,83 $US por FDOT; 6,54 $US por LVDOT; y 5,35 para RVDOT. Los análisis 
de sensibilidad respaldaron los resultados principales.
Se calcularon ahorros considerables en los costos al aumentar la utilizatión de VDOT. La optión 
RVDOT sería la modalidad de minimizatión de costos, al suponer una equivalencia en la adhesión, 
la duratión, la completión y las reacciones adversas al tratamiento con todos los tipos de DOT.
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The US national incidence rate for tuberculosis (TB) cases in 2016 was 2.9 per 100 000 
population.1 Treatment for TB disease usually requires 6 months or longer with multiple 
drugs. Treatment adherence is critical to successful patient outcomes.2 Directly observed 
therapy (DOT) is the standard of care in New York City (NYC) to ensure proper adherence 
during the treatment of TB disease; however, it is a resource intensive intervention.
DOT involves trained individuals observing each dose of anti-TB medication administered 
for the duration of treatment. DOT can be conducted through face-to-face (in-person) or 
electronic observation, including videoconferencing and recorded-video sessions (VDOT).3 
In prior studies, use of live-videoconferencing or recorded-video DOT (LVDOT, RVDOT) 
has been shown to promote treatment adherence and completion outcomes similar to in-
person clinic and field-based DOT (CDOT, FDOT).4–7 VDOT was also shown to be highly 
accepted by patients and health-care providers.8 Program savings associated with reduced 
travel and staff time for telehealth strategies are potentially substantial, although studies are 
limited.7,9–11
The NYC Department of Health and Mental Hygiene (DOHMH) provides DOT at four 
clinics, homes, worksites and locations requested by patients. Patients eligible for DOT 
include those on treatment for TB disease (e.g., confirmed or probable TB cases), and 
certain patients treated for latent TB infection (e.g., household contacts of infectious TB 
patients).5,12 The DOHMH offers four types of DOT: CDOT, FDOT, LVDOT, and RVDOT.
We conducted a cost-minimization analysis to estimate and compare the costs of offering 
each DOT type in NYC. Our study objectives were 1) to calculate labor and non-labor costs 
associated with all DOT types offered by the DOHMH, 2) to calculate per-session and 
annual program costs to implement DOT, and 3) to assess cost impacts when re-assigning 
the observed DOT sessions to alternative types (i.e., cost attribution).
METHODS
Cost analysis
This study used a retrospective, bottom-up micro-costing cost-minimization evaluation 
methodology taking the TB program perspective.13–15 Cost-minimization analyses identify 
and compare costs of interventions while assuming equivalent health outcomes between 
types,16 thereby focusing solely on cost differences to inform program evaluation.17 This 
methodology has previously been used in analyses of TB treatment activities.18 Costs were 
calculated for all DOT sessions conducted by the DOHMH TB program during September 
2014–August 2015. The cost data from 2016 were applied to resource utilization in the study 
period due to the unavailability of cost information. Labor and non-labor cost inputs were 
obtained from the DOHMH TB program except for gasoline costs, which were obtained 
through the New York State Energy Research and Development Authority.19 The analysis 
focused on cost per DOT session, rather than per patient, since some patients receive DOT 
from non-DOHMH providers for part of their treatment.
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Labor costs
Labor costs per minute were estimated by taking the annual salary plus fringe benefits for 
each DOT worker and dividing by the minutes in 261 paid 7-hour working days (including 
holidays). DOT staff, who are trained, non-licensed professionals, range in job titles and 
salaries; therefore, we calculated the cost per session for each of the 17 DOT workers by 
multiplying cost per minute with each DOT type’s observation time. The duration of one 
LVDOT session was previously observed to be 5 minutes.5 We assumed the same duration 
for CDOT and one half of the LVDOT observation time (2.5 minutes) for RVDOT, since no 
real-time interactions occur during RVDOT sessions. For FDOT, we assumed the same 
observation time as for LVDOT plus one-way travel time. The per-session labor cost was the 
average of all the workers’ cost per session for each DOT type.
To calculate the FDOT travel times, we reviewed vehicle travel logs completed as part of 
standard program practice. Only DOT-specific trips submitted by DOT workers using 
designated vehicles were included. We randomly selected one weekday every 2 weeks 
(excluding holidays) from January 2014 through August 2014 and from January 2015 
through August 2015 to obtain a representative sample of travel. The miles traveled and the 
travel times between locations were calculated. We excluded trips where neither the arrival 
nor departure site was a DOT location (e.g., relocation of vehicles for parking). We also 
excluded non-DOT trips (e.g., maintenance, hospital visits) and incomplete records—
missing or illegible mileage information or data entry errors (e.g., negative mileage). Logs 
with missing travel times were excluded from the average travel time calculation.
Non-labor costs
Non-labor cost inputs included resources used for one or multiple DOT types. Costs 
associated with multiple program activities, which could not be separated from DOT, were 
excluded (e.g., administrative costs for operating clinics). Additionally, only costs directly 
incurred by the TB program were included in the analysis, which excludes other DOHMH 
and city government expenses (e.g., insurance). Table 1 shows the non-labor costs.
Based on the mileage logs, the average daily miles traveled for FDOT were aggregated by 
month and divided by the number of working days in that month. Fuel economy for hybrid 
sedans was assumed to be 30 miles per gallon of gasoline. The mean daily travel cost was 
the average daily distance in miles per gallon multiplied by the 2016 monthly per-gallon 
gasoline costs for the NYC metropolitan area.19 The number of daily FDOT sessions was 
the total number of one-way trips in that month divided by the number of person-days. 
Travel cost per session was the mean daily travel cost divided by the average FDOT sessions 
per day.
To calculate the total per-session costs, we defined a steady state of DOT implementation 
comprising equal use of all DOT types (i.e., 25% RVDOT, 25% LVDOT, 25% FDOT, 25% 
CDOT), given the average daily DOT capacity, which was the sum of observed DOT 
sessions across all DOT types divided by 247 working days. For all non-labor assets (e.g., 
webcams, signature pads, headsets, and tablets), we determined a 3-year useful life and a 
depreciation rate of one third. This rate, multiplied by the total asset cost, derives the annual 
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cost assuming zero salvage value. Cost per day was the total cost of each non-labor input 
divided by 247 working days. Cost per session was the cost per day divided by the number 
of steady state sessions per day. The total non-labor cost per session for each DOT type was 
the sum of their costs of inputs per session.
Cost attribution analyses
Cost attribution analysis captures the changes in resource use as the parameters of the 
intervention are modified. We modified the proportions of DOT utilization and multiplied by 
the program’s total DOT capacity to identify the number of sessions for each DOT type. We 
multiplied these by the total per-session costs and examined the savings potential. We 
identified 35 implementation scenarios for the attribution analysis by adjusting the DOT 
proportions at quartile increments (0, 0.25, 0.50, 0.75, and 1) and choosing a proportion for 
each DOT type where the sum of the proportions equals one. We hypothesized that increased 
use of VDOT would significantly (P < 0.05) decrease the annual program cost.
We applied four bivariate generalized linear models to the scenario data to predict the 
average changes in cost outcome. We created four ordinal variables, one for each DOT type. 
Each variable indicated the quartile of utilization for that DOT type. For example, in a 
scenario where only RVDOT is used, the variable for RVDOT would indicate a value of ‘4,’ 
as 100% utilization describes the highest quartile. The variables for all other DOT types 
would equal ‘0.’ Three sensitivity checks were conducted on the re-attributed data set: 1) re-
allocating non-labor inputs across VDOT types, 2) increasing RVDOT session time to match 
LVDOT, and 3) evaluating the economies of scale assumption.
Microsoft Excel (Microsoft Corp, Redmond, WA, USA) was used to generate random dates 
for assessing the DOT logs and to develop the data tables for the cost analysis. Regression 
analyses were implemented using Stata v14 (StataCorp, College Station, TX, USA).
Ethics
This analysis was considered a public health program evaluation activity and did not require 
review by the DOHMH Institutional Review Board (IRB). This project was reviewed by the 
Centers for Disease Control (Atlanta, GA, USA) and determined to not be research requiring 
IRB review.
RESULTS
Between September 2014 and August 2015, there were 38 035 unique DOT sessions with 
the following distribution: CDOT 12 002 (32%); FDOT 15 483 (41%); LVDOT 7185 (19%); 
and RVDOT 3365 (9%), and with the following average DOT sessions per day: CDOT 49; 
FDOT 63; LVDOT 29; and RVDOT 14. The total annual cost for all DOT delivery in the 
study period in $US was $476 405: $102 494 for CDOT; $308 521 for FDOT; $46 927 for 
LVDOT; and $18 463 for RVDOT. The total cost per session was $8.46 for CDOT, $19.83 
for FDOT, $6.54 for LVDOT, and $5.35 for RVDOT (Table 2). Per-session cost derivations 
showed both RVDOT and LVDOT costs to be lower than CDOT and FDOT costs. The 
Figure shows that FDOT comprised approximately 65% of the total cost and an even greater 
proportion (83%) of the total labor cost for DOT.
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Cost inputs
Of 34 randomized days, 33 had FDOT observations conducted and 2494 one-way trips were 
identified with 223 (8.9%) trips excluded due to incomplete records or identification as non-
DOT trips. Of 2271 trips included in the mileage calculations, 1703 (75%) were retained to 
calculate the average FDOT travel time; the others were excluded due to incomplete or 
inaccurate times. The mean travel time was 27.43 minutes (interquartile range [IQR] 15–35). 
The average miles traveled per person-day was 38.4 miles and the average steady state per-
session gasoline cost was $0.34.
The average annual salary was $47 353. Average labor costs per session were $2.91 for 
CDOT, $18.67 for FDOT, $2.91 for LVDOT, and $1.47 for RVDOT. Notably, $15.21 (81%) 
of the FDOT labor cost per session was attributed to travel time. Table 1 shows the non-labor 
cost components.
Cost attribution analysis
Table 3 summarizes the cost impacts in the attribution analysis. We started by assuming that 
one DOT type is unused and the others are held in equal proportions (33%). We then 
increased the use of that DOT type by 25% (one quartile) and estimated the new total 
program cost. The mean cost for DOT without using RVDOT was $422 938 (model 4). For 
each quartile increase in RVDOT utilization, we noted a 16% decrease (P < 0.001) in the 
total costs to $359 232 (95% confidence interval [CI] $332 743–$387 830), keeping the non-
labor input allocations unchanged. By comparison, each quartile increase of LVDOT use 
produced an 11% decline (model 3; P = 0.01), and for FDOT, there was a 30% increase 
(model 2; P < 0.01). Using a uniform distribution of DOT delivery (25% for each DOT type, 
or 9510 sessions each), the total annual cost was $382 145 (or $10 using a per-session 
average basis), reflecting a 20% reduction in cost.
Sensitivity analyses
First, we re-distributed the patient phones equally across VDOT types, which did not 
statistically change the absolute cost outcome for RVDOT ($359 433, 95%CI $331 670–
$389,521; P = 0.003). Second, we increased the per-session RVDOT observation time from 
2.5 to 5 min, resulting in a smaller decrease, from 16% to 11% (P = 0.003), matching the 
LVDOT cost outcome. Finally, we reduced the program capacity for each DOT type by 10%, 
which increased the cost for a one quartile increase in RVDOT to $369 733 (an increase of 
3%, or approximately $10 500). The sensitivity analyses demonstrated the robustness of 
RVDOT as a cost-minimizing DOT type.
DISCUSSION
The use of VDOT has increased among US TB programs in recent years.3 While some 
studies demonstrated equivalent treatment outcomes using VDOT, few studies have assessed 
its economic value to public health programs. Our study calculated both annual and per-
session costs of four different DOT types in NYC, which represents a novel contribution due 
to the multiple DOT types assessed and the volume of observation data included. We 
subsequently offered another noteworthy addition by estimating the cost savings with the 
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increased utilization of either type of VDOT offered by the DOHMH. We identified RVDOT 
as the modality that most minimized costs, assuming equivalent treatment adherence, 
duration, completion, and adverse events across the DOT types. However, the sensitivity 
analysis indicated that the cost savings for RVDOT would be similar to LVDOT if the 
observation time matched.
There were limitations with the mileage logs. First, a sample of FDOT trips encompassing 8 
months prior to and 8 months during the study period was used due to missing logs during 
the study period, potentially resulting in different numbers of per-day FDOT trips, mileage, 
and time. Second, we were unable to use the exact number FDOT observations (e.g., trips 
with multiple patients at one location) to calculate per-session travel time and distance, 
potentially increasing the FDOT costs. However, we expect our sample contained few trips 
with multiple observations. Third, public transportation was excluded due to unavailable 
data on the number of visits and travel times. However, as FDOT costs mostly consist of 
labor, including public transportation, which requires more time, this will likely increase 
FDOT costs.
Another limitation to this study is that only DOT costs directly incurred by the TB program 
were used. We excluded costs absorbed by the NYC Health Department such as insurance, 
purchase, and maintenance costs for vehicles and clinics’ operating costs. Including these 
would increase the annual cost for FDOT and CDOT. Other costs not incorporated into these 
estimates (Table 1) include the LVDOT software cost, which was not directly incurred by the 
program, and phone purchase costs. The exclusion of phone purchase costs, for VDOT, may 
mirror localities where patients must use their personal devices. Furthermore, nursing 
salaries were excluded. In NYC, nurses perform observations for injectable medications and 
occasionally for oral medications. Excluding these salaries represents an underestimate in 
labor costs. Labor costs also did not capture time spent resolving VDOT issues. As 
previously reported, technology problems occur for both patients and Health Department 
staff.5 However, as the technology evolves and the patient population becomes more 
comfortable and adept with technology, we anticipate that fewer problems requiring 
assistance will occur.
This economic evaluation assessed cost inputs for four types of DOT to calculate the annual 
and per-session costs. Using known distributions of utilization by DOT type, we estimated 
potential savings through increased utilization of VDOT. Although not statistically 
significant, CDOT also presented a viable alternative. If costs for operating clinics were 
included, however, potential savings would likely decrease. This evaluation focused solely 
on costs from a TB program perspective, excluding patient considerations. Patients’ time 
and travel costs would likely also increase the cost of CDOT and contribute evidence for 
increasing the utilization of VDOT. An ongoing Centers for Disease Control (Atlanta, GA, 
USA) evaluation (CDC-RFA-PS15–150103CONT17) compares costs from a societal 
perspective. Finally, the current evaluation focused on per-sessions costs based on the known 
DOT utilization of the TB program. Analyses assessing DOT costs for monitoring patients 
through the end of treatment, while factoring in patient and disease characteristics as well as 
outcomes, would provide an alternate and informative perspective for TB programs.
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In striving to provide more patient-centered care, offering a single DOT type may not be the 
optimal solution even if it generates the greatest savings. Some patients require alternate 
means of treatment monitoring (e.g., experienced adverse events, needs in-person 
evaluation). For these situations, offering multiple DOT types allows the program to 
accommodate individual patient needs. Our results support adopting a strategy with multiple 
DOT types to accommodate complex treatment needs while encouraging VDOT when 
possible to lower costs. Other TB programs may apply similar methodology to assess cost 
savings when developing a DOT strategy.
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Figure. 
Annual total (top) and labor costs (bottom) by DOT type based on utilization between 
September 2014 and August 2015 in New York City, NY, USA. CDOT = clinic-based DOT; 
FDOT = field-based DOT; LVDOT = live-video DOT; RVDOT = recorded-video DOT.
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